金寶通(00320.HK)上半財年純利達3415.6萬港元 同比大增15.2倍
格隆匯11月25日丨金寶通(00320.HK)公吿,截至2021年9月30日止6個月,公司收益為18.36億港元,同比增長22.26%;公司擁有人應占溢利為3415.6萬港元,同比增長1521.84%;每股盈利為4.06港仙 。
儘管經營環境嚴峻,集團仍得以在營運及財務表現上取得佳績。期內,受惠於消費者信心及訂單量回升,以及新客户與戰略合作夥伴的銷售持續增長,集團收入同比大幅上升22.3%。加上銷售組合及生產規模效應的提升,毛利同比增長48.5%至2.56億港元,毛利率亦輕微上升2.4個百分點至13.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.